baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

Soc. Generale Knock-Out GILD/ DE000SW2V4Q1 /

30/08/2024 21:45:09	Chg.-0.03	Bid22:00:38	Ask22:00:38	Underlying	Strike price	Expiration date	Option type
4.57EUR	-0.65%	- Bid Size: -	- Ask Size: -	Gilead Sciences Inc	54.0895 USD	31/12/2078	Call

GlobeNewswire 08/08 HOOKIPA Pharma Reports Second Quarter 2024 Financial Results and Recent Business Highlights

GlobeNewswire 08/08 Assembly Biosciences Reports Second Quarter 2024 Financial Results and Recent Updates

GlobeNewswire 08/08 Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2024 Financial Results

GlobeNewswire 06/08 MacroGenics Provides Update on Corporate Progress, Second Quarter 2024 Financial Results

GlobeNewswire 05/08 89bio Reports Second Quarter 2024 Financial Results and Corporate Updates

GlobeNewswire 05/08 89bio Appoints Charles McWherter, Ph.D., to its Board of Directors

GlobeNewswire 01/08 Merus Announces Financial Results for the Second Quarter 2024 and Provides Business Update

GlobeNewswire 23/07 ACTG Presents Data Analysis at AIDS 2024 Showing Association between Elevated Risk of Cardiovascular...

GlobeNewswire 15/07 Assembly Biosciences Presents New Preclinical Data Highlighting Investigational Helicase-Primase Inh...

GlobeNewswire 08/07 Memo Therapeutics AG appoints Paul Carter as Chairperson

GlobeNewswire 04/07 Burns McClellan Mourns the Passing of Founder and CEO, Lisa Burns

GlobeNewswire 01/07 HOOKIPA Pharma Announces First Person Dosed in Phase 1b Clinical Trial of HB-500 for the Treatment o...

GlobeNewswire 01/07 Vera Therapeutics Announces Appointment of Industry Veteran David L. Johnson as Chief Operating Offi...

GlobeNewswire 28/06 Ensho Therapeutics Launches with Phase 2-Ready Oral α4β7 Inhibitor for Inflammatory Bowel Disease

GlobeNewswire 26/06 Neurona Therapeutics Appoints Dr. Nadia Agopyan as Senior Vice President of Regulatory Affairs

GlobeNewswire 26/06 Oruka Therapeutics Announces Key Additions to Leadership Team and Board of Directors

TeleTrader 20/06 US opens mostly higher after labor, housing data

GlobeNewswire 18/06 Assembly Biosciences Doses First Participant in Phase 1b Clinical Trial Evaluating Next-Generation C...

GlobeNewswire 17/06 Assembly Biosciences Announces $12.6 Million in Equity Financings

GlobeNewswire 10/06 Assembly Biosciences Doses First Participant in Phase 1a/b Clinical Trial of Herpes Simplex Virus He...

GlobeNewswire 22/05 Assembly Biosciences to Present Data at Upcoming International Herpesvirus Workshop and EASL Congres...

GlobeNewswire 14/05 Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2024 Financial Results

GlobeNewswire 09/05 MacroGenics Provides Update on Corporate Progress, First Quarter 2024 Financial Results and Interim ...

GlobeNewswire 09/05 HOOKIPA Pharma Reports First Quarter 2024 Financial Results and Recent Business Highlights

Soc. Generale Knock-Out GILD/ DE000SW2V4Q1 /

If you wish to receive reply to your feedback, please provide your email address.